title: Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
abstract: Dilated cardiomyopathy (DCM) is the third cause of heart failure and the most frequent cause of heart transplantation (HT). The value of biomarkers in prognostic stratification may be important to identification the patients for more advanced treatment. Assessment of serum Galectin-3 (Gal-3) and ST2 as biomarkers of unfavorable outcome (death and combined endpoint: HT or death or left ventricular assist device implantation) in stable DCM patients. 107 DCM patients age 39-56 years were included into the study and followed-up for mean 4.8 years. Gal-3 and ST2 concentrations were measured ELISA tests. Clinical data, treatment, laboratory parameters, NT-proBNP, Gal-3 and ST2 measured at time of inclusion were assessed as risk factors for reaching the study endpoints using log rank test and Cox proportional-hazards model. During follow-up 27 patients died, 40 achieved combined endpoint. ROC curves indicated cut-off value of ST2-17.53 ng/ml, AUC-0.65 (0.53-0.76) and of NT-proBNP-669 pg/ml, AUC 0.61 (0.50-0.73) for prediction of death. In multivariate analysis ST2 was predictor of death (HR per unit increase in log ST2 2.705, 95 % CI 1.324-5.528, P=0.006) and combined endpoint (HR per unit increase in log ST2 2.753, 95 % CI 1.542-4.914, P<0.001). NT-proBNP was predictive variable only for death in multivariate analysis. Gal-3 concentration was not associated with adverse outcome. ST2 but not Gal-3 may be useful for predicting adverse outcome in stable dilated cardiomyopathy patients.
authors.affiliation: Medical University of Silesia, School of Medicine with the Division of Dentistry, Second Department of Cardiology, Zabrze, Poland.
authors.forename: Celina
authors.initials: C
authors.lastname: Wojciechowska
authors.affiliation: Medical University of Silesia, School of Medicine with the Division of Dentistry, Department of Biochemistry, Zabrze, Poland. Electronic address: eromuk@gmail.com.
authors.forename: Ewa
authors.initials: E
authors.lastname: Romuk
authors.affiliation: Medical University of Silesia, School of Medicine with the Division of Dentistry, Second Department of Cardiology, Zabrze, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Nowalany-Kozielska
authors.affiliation: Medical University of Silesia, School of Medicine with the Division of Dentistry, Second Department of Cardiology, Zabrze, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Jacheć
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D018450:Disease Progression; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D037502:Galectin 3 / Q000097:blood*; D037161:Galectins; D006801:Humans; D000072179:Interleukin-1 Receptor-Like 1 Protein / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D017472:Receptors, Interleukin-1; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D037502:Galectin 3; D037161:Galectins; C079241:IL1RL1 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein; C428445:LGALS3 protein, human; D017472:Receptors, Interleukin-1
keywords: Dilated cardiomyopathy; Gaectin-3; Heart failure; ST-2